Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L

RCT (n=275) found that brigatinib therapy was linked to superior progression free survival vs crizotinib after a median follow-up of 24.9 months (24.0 vs 11.0 months, HR for progression or death = 0.49, 95% CI 0.35-0.68).

Journal of Clinical Oncology